Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446159 · ClinicalTrials.gov registry record · Phase 2
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
A Phase 2 study of Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 188
- Enrollment target
- 20
- Study locations
NCT01446159 is a Phase 2 study of Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer that has completed, run by MedImmune. The registered enrollment target is 188 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT01446159, a Phase 2 study of Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 188 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
Conditions Studied
Interventions
- DRUG Aromatase Inhibitor
- DRUG MEDI-573
Study Locations (20)
Maryland
- Research Site - Baltimore
- Research Site - Baltimore
- Research Site - Bethesda
- Research Site - Frederick
- Research Site - Rockville
Florida
- Research Site - Fort Myers
- Research Site - Orlando
- Research Site - Port Saint Lucie
- Research Site - St. Petersburg
Georgia
- Research Site - Athens
- Research Site - Augusta
- Research Site - Lawrenceville
California
- Research Site - Bakersfield
- Research Site - Pleasant Hill
Michigan
- Research Site - Ann Arbor
- Research Site - Lansing
Arizona
- Research Site - Scottsdale
Connecticut
- Research Site - Stamford
Maine
- Research Site - Scarborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2011-06-13 |
| Est. Completion | 2019-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01446159
The ClinicalTrials.gov registry entry for NCT01446159 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Aromatase Inhibitor is the first listed.
NCT01446159 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Maryland, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01446159 about?
NCT01446159 is a clinical study titled "Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer". Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
What is the current status of trial NCT01446159?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 188 participants. The study started on 2011-06-13. Estimated completion is 2019-06-28.
What conditions does trial NCT01446159 study?
This clinical trial studies the following conditions: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
What interventions are being tested in trial NCT01446159?
The interventions under investigation include: Aromatase Inhibitor (DRUG), MEDI-573 (DRUG).
Who is sponsoring clinical trial NCT01446159?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01446159 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.